Introduction: The introduction and exploration of novel agents has significantly improved patient outcome in the treatment of multiple myeloma (MM). One such compound, bortezomib, was the first proteasome inhibitor (PI) to be approved as a MM therapeutic. The efficacy and safety data provided by bortezomib usage has provided the basis for the development of a second generation of PIs.Areas covered: This review focuses on PIs that are currently under evaluation in Phase II clinical trials for the treatment of MM. Furthermore, the article summarizes the currently understood mechanisms of action and the available clinical data for its use in MM.Expert opinion: Second generation PIs have demonstrated promising activity in patients with advanced-stage myeloma, including those refractory to bortezomib. It should be noted, however, that their efficacy in upfront settings is currently under investigation. Future PI development should include schedule optimization and the investigation of PIs potential synergistic activity with other anti-myeloma agents. © 2014 Informa UK, Ltd.

Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma

Bringhen S.
First
;
Gay F.;Donato F.;Troia R.;Mina R.;Palumbo A.
Last
2014

Abstract

Introduction: The introduction and exploration of novel agents has significantly improved patient outcome in the treatment of multiple myeloma (MM). One such compound, bortezomib, was the first proteasome inhibitor (PI) to be approved as a MM therapeutic. The efficacy and safety data provided by bortezomib usage has provided the basis for the development of a second generation of PIs.Areas covered: This review focuses on PIs that are currently under evaluation in Phase II clinical trials for the treatment of MM. Furthermore, the article summarizes the currently understood mechanisms of action and the available clinical data for its use in MM.Expert opinion: Second generation PIs have demonstrated promising activity in patients with advanced-stage myeloma, including those refractory to bortezomib. It should be noted, however, that their efficacy in upfront settings is currently under investigation. Future PI development should include schedule optimization and the investigation of PIs potential synergistic activity with other anti-myeloma agents. © 2014 Informa UK, Ltd.
23
9
1193
1209
https://www.tandfonline.com/doi/full/10.1517/13543784.2014.920821
Bortezomib; Multiple myeloma; Novel agents; Proteasome inhibitors; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Drug Design; Humans; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Pyrazines
Bringhen S.; Gay F.; Donato F.; Troia R.; Mina R.; Palumbo A.
File in questo prodotto:
File Dimensione Formato  
[POST-PRINT Author version] Bringhen et al - 2014 - Phase II investigational PIs in MM.pdf

Accesso riservato

Descrizione: [POST-PRINT Author version] Bringhen et al - 2014 - Phase II investigational PIs in MM
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 668.02 kB
Formato Adobe PDF
668.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1760020
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact